A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users.
Acne
Contraceptive implant
Drug interaction
Etonogestrel
Isotretinoin
Journal
Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
23
01
2020
revised:
23
03
2020
accepted:
09
04
2020
pubmed:
24
4
2020
medline:
16
10
2021
entrez:
24
4
2020
Statut:
ppublish
Résumé
To explore the pharmacokinetic interaction between isotretinoin, a cytochrome P-450 (CYP) inducer and potent teratogen, and the etonogestrel contraceptive implant. We enrolled healthy reproductive-age women initiating isotretinoin and using an etonogestrel implant. We compared serum etonogestrel concentrations at baseline and after four and nine weeks of isotretinoin co-administration using a validated assay. Among eight implant users, all serum etonogestrel concentrations remained >90 pg/mL during isotretinoin co-administration with no significant changes from baseline (p = 0.25, Friedman's test). In this exploratory study, we found that isotretinoin did not cause serum etonogestrel concentrations to fall below the threshold for ovulatory suppression (<90 pg/mL) among implant users. Reproductive-age women treated with isotretinoin require reliable contraception to prevent pregnancies impacted by teratogenic-effects. This small study demonstrates that contraceptive implant users maintained serum etonogestrel concentrations above the threshold for consistent ovulatory suppression during isotretinoin co-administration. The contraceptive implant remains an appropriate option for patients considering isotretinoin therapy.
Identifiants
pubmed: 32325076
pii: S0010-7824(20)30126-8
doi: 10.1016/j.contraception.2020.04.011
pmc: PMC7272275
mid: NIHMS1586020
pii:
doi:
Substances chimiques
Contraceptive Agents, Female
0
Drug Implants
0
etonogestrel
304GTH6RNH
Desogestrel
81K9V7M3A3
Isotretinoin
EH28UP18IF
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
58-60Subventions
Organisme : NICHD NIH HHS
ID : K12 HD001271
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001082
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002535
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Clin Pharmacol Ther. 2004 May;75(5):464-75
pubmed: 15116059
Ther Drug Monit. 2013 Dec;35(6):844-8
pubmed: 24081205
N Engl J Med. 1995 Jul 13;333(2):101-6
pubmed: 7777014
Contraception. 2017 Jun;95(6):571-577
pubmed: 28288788
Obstet Gynecol. 2019 Apr;133(4):783-794
pubmed: 30870275
Contraception. 2019 Jul;100(1):37-41
pubmed: 30980827
Front Endocrinol (Lausanne). 2014 Oct 20;5:175
pubmed: 25368605
Arch Dermatol Res. 1994;286(2):104-6
pubmed: 8154922
Skin Pharmacol Physiol. 2014;27 Suppl 1:3-8
pubmed: 24280643
Ann Pharmacother. 2001 Mar;35(3):329-36
pubmed: 11261531
J Am Acad Dermatol. 2016 May;74(5):945-73.e33
pubmed: 26897386
MMWR Recomm Rep. 2016 Jul 29;65(3):1-103
pubmed: 27467196